# A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure

> **NCT02086825** · PHASE3 · WITHDRAWN · sponsor: **NYU Langone Health**

## Conditions studied

- Hepatic Encephalopathy

## Interventions

- **DRUG:** Rifaximin
- **DRUG:** Lactulose

## Key facts

- **NCT ID:** NCT02086825
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-10
- **Primary completion:** 2016-12
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02086825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02086825, "A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02086825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*